Skip to main content
Fig. 1 | BMC Cancer

Fig. 1

From: The association between immune-related adverse events and survival outcomes in Asian patients with advanced melanoma receiving anti-PD-1 antibodies

Fig. 1

Severity and types of irAEs in melanoma patients receiving anti-PD-1 antibodies. a The numbers of patients experiencing different grades and types of irAEs. b The first day of irAEs after ICIs based on different types of irAEs. e Grouping based on the first day of irAE occurrence. irAEs, immune-related adverse events; ICIs, immune checkpoint inhibitors

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us